“We see the reward as positively skewed on a risk-adjusted basis,” analysts at Leerink Partners wrote, citing improving ...

“We see the reward as positively skewed on a risk-adjusted basis,” analysts at Leerink Partners wrote, citing improving trends in Aetna and Health Care Benefits (HCB). The firm noted that CVS ...

Leerink analyst Michael Cherny upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55. The firm ...

Investing.com -- CVS Health is seeing signs of stabilization in key business areas, prompting Leerink Partners to upgrade the stock from Market Perform to Outperform and raise its price target to $75 ...